In the subjects who received TransCon PTH 24 μg PTH(1‐34)/day, AEs reflected the known pharmacology of PTH, ie, vasodilatation (as well as hypercalcemia), leading to orthostatic hypotension, lightheadedness, tachycardia, and syncope; similar AEs were seen in the placebo‐treated subjects in this cohort as well. The gene discussed is PTH; the disease is hypercalcemia disease.